Bryn Mawr Capital Management LLC Sells 6,206 Shares of Pfizer Inc. (NYSE:PFE)

Bryn Mawr Capital Management LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 3.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 194,035 shares of the biopharmaceutical company’s stock after selling 6,206 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Pfizer were worth $5,429,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Olistico Wealth LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer during the second quarter worth about $29,000. Creekmur Asset Management LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC boosted its holdings in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. bought a new stake in Pfizer during the 2nd quarter worth approximately $34,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 1.0 %

Shares of NYSE:PFE traded up $0.29 during mid-day trading on Friday, reaching $29.01. The stock had a trading volume of 37,137,599 shares, compared to its average volume of 38,496,418. The firm has a market cap of $164.39 billion, a PE ratio of -483.33, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69. The firm has a 50 day simple moving average of $28.97 and a two-hundred day simple moving average of $28.00. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $36.29.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period last year, the firm posted $0.67 earnings per share. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, research analysts predict that Pfizer Inc. will post 2.68 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.79%. Pfizer’s dividend payout ratio (DPR) is currently -2,800.00%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research analyst reports. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Barclays upped their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. UBS Group upped their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.